{"entity":{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","aka":["senaparib","IMP4297","IMP4927","Sepalna"],"tldr":"Senaparib is an oral PARP inhibitor from IMPACT Therapeutics tested as maintenance treatment after first-line chemotherapy for advanced ovarian cancer. On 17 September 2026 the EMA's medicines committee recommended EU approval under the name Sepalna; the European Commission's decision is pending.","summary":"Senaparib (IMP4297; the registry's spelling of the code is IMP4927) is a small-molecule PARP inhibitor developed by IMPACT Therapeutics. The phase 3 study NCT04169997 (FLAMES, 404 participants) tested it as monotherapy maintenance after first-line chemotherapy in advanced ovarian cancer. On 17 September 2026 the CHMP adopted a positive opinion recommending a marketing authorisation for Sepalna (applicant SFL Pharmaceuticals Deutschland GmbH) as monotherapy for the maintenance treatment of adults with advanced (FIGO stage III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response after first-line platinum-based chemotherapy. The register gives the benefit as longer progression-free survival than placebo and lists anaemia, leukopenia, neutropenia, thrombocytopenia, nausea, raised transaminases and fatigue first among the most common side effects. The status stays at phase 3 until the European Commission decides. No efficacy figures are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of IMP4927","url":"https://clinicaltrials.gov/search?intr=IMP4927"},{"label":"Sponsor page","url":"https://www.impacttherapeutics.com"},{"label":"EMA: Sepalna (senaparib), CHMP opinion 17 September 2026","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/sepalna"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":["impact-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04169997"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Mechanism, indication wording, applicant and opinion date read from the EMA register page for Sepalna on 24 September 2026 (PR 74 review); before that the record said the target was not stated."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"brand":"Sepalna","modality":"small molecule (oral PARP inhibitor)","mechanism":"Inhibitor of poly(ADP-ribose) polymerase (PARP), ATC code L01XK07, that blocks the repair of damaged DNA in cancer cells and causes them to die (EMA summary of opinion, 17 September 2026).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/imp4927/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"company":[{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"}],"trial":[{"id":"nct04169997","kind":"trial","name":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","route":"/trials/nct04169997/"}]}}